Ming-Han Yang1, I-Chun Chen2, Yen-Shen Lu3. 1. Department of Oncology, National Taiwan University Hospital, Taiwan; Department of Oncology, National Taiwan University Cancer Center, Taiwan. 2. Department of Oncology, National Taiwan University Hospital, Taiwan; Department of Oncology, National Taiwan University Cancer Center, Taiwan; Graduate Institute of Oncology, National Taiwan University, Taiwan. 3. Department of Oncology, National Taiwan University Hospital, Taiwan; Department of Oncology, National Taiwan University Cancer Center, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, Taiwan. Electronic address: yslu@ntu.edu.tw.
Abstract
PURPOSE: Metaplastic carcinoma of the breast (MCB) is a rare cancer characterized by the histologic presence of two or more histological cell types originating from epithelial and mesenchymal stem cells. Patients with metastatic MCB have a low response rate to conventional chemotherapy and poor survival. Optimal treatment strategies for metastatic MCB are urgently needed. METHODS: We retrospectively reviewed a patient who had enrolled in the phase II/III seamless study, BELLE-4 (NCT01572727). The patient's response to the study drug assessed by an investigator per protocol and clinical course were examined and compared with those of the main cohorts in the BELLE-4 study. RESULTS: Our patient exhibited metastatic MCB and received systemic chemotherapy, paclitaxel (70 mg/m2/week) and buparlisib (80 mg/day), a pan-class I phosphatidylinositol-3 kinase (PI3K) inhibitor. The optimal response was a confirmed partial response for 17 months in total. During the compassionated use program period, the tumor regrew when buparlisib was stop because of toxicity, and responded to the treatment again after resumed the buparlisib treatment. The overall survival of the patient after the development of metastatic MCB was 42 months. She experienced grade 3 hyperglycemia similar to that observed in the main cohort. CONCLUSION: Buparlisib plus weekly paclitaxel might be a new treatment option for patients with metastatic MCB harboring a PIK3CA mutation. Additional prospective studies for investigating the efficacy of the proposed combination are warranted.
PURPOSE: Metaplastic carcinoma of the breast (MCB) is a rare cancer characterized by the histologic presence of two or more histological cell types originating from epithelial and mesenchymal stem cells. Patients with metastatic MCB have a low response rate to conventional chemotherapy and poor survival. Optimal treatment strategies for metastatic MCB are urgently needed. METHODS: We retrospectively reviewed a patient who had enrolled in the phase II/III seamless study, BELLE-4 (NCT01572727). The patient's response to the study drug assessed by an investigator per protocol and clinical course were examined and compared with those of the main cohorts in the BELLE-4 study. RESULTS: Our patient exhibited metastatic MCB and received systemic chemotherapy, paclitaxel (70 mg/m2/week) and buparlisib (80 mg/day), a pan-class I phosphatidylinositol-3 kinase (PI3K) inhibitor. The optimal response was a confirmed partial response for 17 months in total. During the compassionated use program period, the tumor regrew when buparlisib was stop because of toxicity, and responded to the treatment again after resumed the buparlisib treatment. The overall survival of the patient after the development of metastatic MCB was 42 months. She experienced grade 3 hyperglycemia similar to that observed in the main cohort. CONCLUSION:Buparlisib plus weekly paclitaxel might be a new treatment option for patients with metastatic MCB harboring a PIK3CA mutation. Additional prospective studies for investigating the efficacy of the proposed combination are warranted.
Authors: Edaise M da Silva; Pier Selenica; Mahsa Vahdatinia; Fresia Pareja; Arnaud Da Cruz Paula; Lorenzo Ferrando; Andrea M Gazzo; Higinio Dopeso; Dara S Ross; Ariya Bakhteri; Nadeem Riaz; Sarat Chandarlapaty; Pedram Razavi; Larry Norton; Hannah Y Wen; Edi Brogi; Britta Weigelt; Hong Zhang; Jorge S Reis-Filho Journal: NPJ Breast Cancer Date: 2021-04-16
Authors: Yongfeng Li; Meng Chen; Barbara Pardini; Mihnea P Dragomir; Anthony Lucci; George A Calin Journal: J Transl Med Date: 2019-09-23 Impact factor: 5.531
Authors: F Coussy; R El Botty; M Lavigne; C Gu; L Fuhrmann; A Briaux; L de Koning; A Dahmani; E Montaudon; L Morisset; L Huguet; L Sourd; P Painsec; S Chateau-Joubert; T Larcher; S Vacher; S Melaabi; A Vincent Salomon; E Marangoni; I Bieche Journal: J Hematol Oncol Date: 2020-02-22 Impact factor: 17.388
Authors: Tejaswini P Reddy; Roberto R Rosato; Xiaoxian Li; Stacy Moulder; Helen Piwnica-Worms; Jenny C Chang Journal: Breast Cancer Res Date: 2020-11-04 Impact factor: 6.466